SCHEMBL22193554

SCHEMBL22193554

Cc1cc(-c2ccnc(C)c2)c(C)c(C(C)C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UHRF1 Q96T88 1/20 0.41
CCNC P24863 2/20 0.40
CDK8 P49336 2/20 0.40
PSEN1 P49768 3/20 0.39
PSEN2 P49810 3/20 0.39
APH1B Q8WW43 3/20 0.39
NCSTN Q92542 3/20 0.39
APH1A Q96BI3 3/20 0.39
PSENEN Q9NZ42 3/20 0.39
DYRK1A Q13627 3/20 0.39
NFATC1 O95644 1/20 0.38
TLR8 Q9NR97 4/20 0.35
TLR7 Q9NYK1 4/20 0.35
TLR9 Q9NR96 2/20 0.35
PIM1 P11309 1/20 0.35
DYRK2 Q92630 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
MAP4K4 O95819 2/20 0.34
CDC7 O00311 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22374010 0.84 CCNC (0.39) UHRF1CCNCCDK8PSEN1PSEN2
SCHEMBL22193555 0.83 ACVR2A (0.44) DYRK1AMTORAAK1
SCHEMBL22374090 0.81 MYC (0.39) TLR8TLR7TLR9AAK1
SCHEMBL25505853 0.77 TRPA1 (0.47) UHRF1CCNCCDK8PSEN1PSEN2
SCHEMBL22681023 0.77 PSEN1 (0.46) CCNCCDK8PSEN1PSEN2APH1B
SCHEMBL21105125 0.74 RPS6KA3 (0.54) UHRF1CCNCCDK8PSEN1PSEN2
SCHEMBL21646546 0.71 NLRP3 (0.44) DYRK1AAAK1
SCHEMBL20743706 0.70 TDO2 (0.39) CCNCCDK8PSEN1PSEN2APH1B
SCHEMBL30684113 0.70 TDO2 (0.39) CCNCCDK8PSEN1PSEN2APH1B
SCHEMBL1896511 0.70 DYRK1A (0.65) UHRF1CCNCCDK8PSEN1PSEN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518739-B2 Sulfonamide carboxamide compounds INFLAZOME LIMITED (IE) 2022-12-06 US disclosed
US-20200216389-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS INFLAZOME LIMITED (IE) 2020-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200216389-A1 NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS NLRP3, NOD1, PYCARD UHRF1 2416/4885CCNC 3298/4885CDK8 2686/4885
US-11518739-B2 Sulfonamide carboxamide compounds NLRP3, PYCARD, NOD1 UHRF1 2197/4885CCNC 3254/4885CDK8 2828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.